How, and how efficiently, can we treat Chlamydia trachomatis infections in women?

Secondo Guaschino, Giuseppe Ricci

Research output: Contribution to journalArticlepeer-review


Several antichlamydial active drugs are available for both non-pregnant and pregnant women, potentially allowing effective prevention of the consequences and transmission of infection. The choice of treatment regimen not only has to consider efficacy, but also side-effects, compliance and the cost of antibiotic drugs. In recent years there have been no significant changes to the guidelines for treating Chlamydia trachomatis infection as no new antibiotic has been included. Inclusion of a new antichlamydial drug in the guidelines must be supported by suitable, randomized trials. Furthermore, how much it will be used in clinical practice will also depend on considerations of a pharmacoeconomic nature.

Original languageEnglish
Pages (from-to)875-888
Number of pages14
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
Issue number6
Publication statusPublished - Dec 2002


  • Antibiotics
  • Azithromycin
  • Chlamydia trachomatis
  • Drug therapy
  • Erythromycin
  • Female genital infections
  • Tetracycline

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'How, and how efficiently, can we treat Chlamydia trachomatis infections in women?'. Together they form a unique fingerprint.

Cite this